Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
Nature Communications|March 31, 2025
Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitisMeritxell Oliva, Mrinal K Sarkar, Michael E March, et al.
Trials|January 24, 2021
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countriesMoses Badio, Edouard Lhomme, Mark Kieh, et al.
Ebiomedicine|April 26, 2023
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryChelsea McLean, Houreratou Barry, Mark Kieh, et al.
Vaccine|November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and UgandaEdward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
Vaccines|August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine RegimenDaniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
Vaccines|August 29, 2024
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the CongoEdward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, et al.
Plos Medicine|January 23, 2015
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysisCharles S Morrison, Pai-Lien Chen, Cynthia Kwok, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2023
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and AdultsAndrew W Lee, Ken Liu, Edouard Lhomme, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialMuhammed O Afolabi, David Ishola, Daniela Manno, et al.
Pageof 25